A. P. Sugunan

A. P. Sugunan

Auto-generated profile, based on publicly available information

A. P. Sugunan

ICMR-Regional Medical Research Centre, Department of Health Research, Ministry of Health & Family Welfare, Port Blair, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2011 in Letters in Applied Microbiology
Verified
Journal Article
Closed access
PDF file
DBDEBDUTTA BHATTACHARYA
DEBDUTTA BHATTACHARYA
HBH. Bhattacharjee
H. Bhattacharjee
RTR. Thamizhmani
R. Thamizhmani
DSD.S. Sayi
D.S. Sayi
ABA. P. Bharadwaj
A. P. Bharadwaj
SRS. Roy
S. Roy

1 June 2012 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
DBDEBDUTTA BHATTACHARYA
DEBDUTTA BHATTACHARYA
DSD. S. Sayi
D. S. Sayi
RTR. Thamizhmani
R. Thamizhmani
HBHaimanti Bhattacharjee
Haimanti Bhattacharjee
ABA. P. Bharadwaj
A. P. Bharadwaj
ASA. P. Sugunan
A. P. Sugunan
The American Journal of Tropical Medicine and Hygiene is a peer-reviewed journal published monthly by the American Society of Tropical Medicine and Hygiene and consists of two complete, sequentially numbered volumes each calendar year. Journal Affiliation: The American Journal of Tropical Medicine and Hygiene is the official scientific journal of the American Society of Tropical Medicine and Hygiene (ASTMH). The Society is a nonprofit, professional organization whose mission is to promote world health by the prevention and control of tropical disease through research and education.

1 May 2015 in Indian Journal of Medical Research
Verified
Journal Article
Open access
HBHaimanti Bhattacharya
Haimanti Bhattacharya
DBDEBDUTTA BHATTACHARYA
DEBDUTTA BHATTACHARYA
SGS.R. Ghosal
S.R. Ghosal
SRSubarna Roy
Subarna Roy
ASA.P. Sugunan
A.P. Sugunan
Background & objectives: Andaman and Nicobar Islands of India, home to six primitive tribes, constituting about 10 per cent of the total population of these Islands have been detected with high endemicity of hepatitis B infection. During 2000, a total of 936 individuals ≤ 45 yr, negative for hepatitis B surface antigen (HBsAg) and antibody anti-HBs were vaccinated with three doses of a recombinant DNA hepatitis B vaccine in two villages of Car Nicobar Islands. The present study was undertaken to evaluate the impact of the hepatitis B vaccination with respect to the persistence of antibodies and incidence of new infections, prevalence of surface gene mutations among the Nicobarese community in the two villages ten years after hepatitis B vaccination. Methods: Follow up samples were collected from 211 individuals who had received three doses of vaccine ten years back and from a control group of 515 non-vaccinated individuals. The HBsAg, anti-HBs and anti-HBc assay results were compared among vaccinated and non-vaccinated groups. HBV DNA was extracted and sequenced from all the samples for detection of mutation. Genotyping and serotyping of the viruses were performed. Results: The results showed that 85.3 per cent of the vaccinated persons retained protective level of antibodies and among the non-vaccinated individuals, 54.2 per cent showed presence of anti-HBs indicating an exposure to the infection. The overall HBsAg positivity among the studies Nicobarese individuals was reduced to 7.4 per cent after 10 years of vaccination. Anti-HBc was positive in 60.6 and 57 per cent among the vaccinated and non-vaccinated individuals, respectively. Overall breakthrough infection of 8.5 per cent was detected among the vaccinated individuals. The predominant genotype and serotype circulating among these tribal populations were D and ayw3, respectively. Interpretation & conclusions: The results of this study showed an overall reduction in the pool of HBsAg carriers because of the vaccination which helped in reducing the HBsAg carrier rate among the non-vaccinated also, probably due to an increase in herd immunity and reduction in the source of infection. Further studies need to be done to evaluate long term benefits of hepatitis B vaccination among these tribes.

27 July 2020 in International Journal of Tropical Insect Science
Verified
Journal Article
Closed access
PDF file
ASArun Sivan
Arun Sivan
ASA.N. Shriram
A.N. Shriram
VPVanamail Perumal
Vanamail Perumal
ASA. P. Sugunan
A. P. Sugunan

1 July 2012
Verified
Open access
RTR. Thamizhmani
R. Thamizhmani
DBDEBDUTTA BHATTACHARYA
DEBDUTTA BHATTACHARYA
DSD.S. Sayi
D.S. Sayi
HBHaimanti Bhattacharjee
Haimanti Bhattacharjee
NMN. Muruganandam
N. Muruganandam
ASA. P. Sugunan
A. P. Sugunan

1 March 2014
Verified
Journal Article
Open access
ASA. P. Sugunan
A. P. Sugunan
HBHaimanti Bhattacharya
Haimanti Bhattacharya
DBDEBDUTTA BHATTACHARYA
DEBDUTTA BHATTACHARYA
AMA. Mandal
A. Mandal
SGS. R. Ghosal
S. R. Ghosal
AMA. K. Mandal
A. K. Mandal
A total of 237 Nicobarese subjects who had received hepatitis B vaccination as part of mass vaccination project during 2000-2001 were screened for anti-HBsAg titres by quantitative ELISA five years after vaccination. Anti-HBsAg antibody was estimated using quantitative ELISA. Proportion of the subjects with protective levels of antibody and geometric mean antibody titres were calculated. Among the 237 study subjects, 213 had received three doses of vaccine, 17 had received two doses and seven had received one dose. The geometric mean titres of anti-HBs antibodies were 201.7, 31.9 and 23.1 mIU/ml among those who received three, two and one dose of vaccine, respectively. Among those who received three doses of vaccination, 85.9 per cent had anti-HBs antibody levels of 10 mIU/ml or more, indicating seroprotection. The difference in the seroprotection rates among those who received three doses of vaccination (85.9%) and those who received less than three doses (58.3%) was significant. Seroprotection rates one month after the first, second and third dose of vaccination were 49.1, 86.9 and 96.7 per cent, respectively. It then declined to 89 per cent by the end of the second year and to 85.5 per cent by the end of the third year, but there was no decline thereafter. Seroprotection rate reached at the maximum one month after the third dose of HBV vaccine. Although about 15 per cent of the vaccinated persons lost seroprotection by the end of the third year, no further loss in seroprotection was observed between the third year and the fifth year.